Canadian cooperative trial cyclophosphamide plasma exchange progressive multiple sclerosis Canadian Cooperative Multiple Sclerosis Study Group non-specific immunosuppression beneficial multiple sclerosis MS placebo-controlled single-masked trial university centres patients laboratory-supported definite MS progressive phase deterioration disability status scale EDSS previous year intravenous cyclophosphamide oral prednisone daily oral cyclophosphamide alternate day prednisone weeks exchange weeks medications plasma exchange patients months mean months monitoring neurologist aware treatment allocation evaluating neurologist primary analysis comparison rates treatment failure worsening neurologist assessment EDSS consecutive assessments significant differences groups primary analysis treatment failures cyclophosphamide plasma exchange placebo differences proportions month assessment mean change EDSS final assessment cyclophosphamide plasma exchange placebo slight trend plasma exchange group months follow-up final assessment study previous reports immunosuppressive treatments stabilisation improvement progressive MS 